Abstract
Candesartan has been reported to produce nitric oxide (NO) and to decrease oxidative stress in animal studies. We investigated candesartan's effect on the production of NO and oxidative stress as well as on carotid intima-media thickness (IMT) in hypertensive patients. One-hundred age-matched hypertensive patients were enrolled into an angiotensin II receptor blocker (ARB) group (n=50) or a non-ARB group (n=50). The ARB group was treated with candesartan 8 mg and, when needed, Ca channel blockers, angiotesin-converting enzyme (ACE) inhibitors, and/or β-blockers. The non-ARB group was treated with drugs other than ARB. Carotid IMT was assessed by echocardiography before and 12 and 24 months after treatment. The urine levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), an indicator of oxidative stress, and the serum levels of NOx, an indicator of NO, were measured. Blood pressure decreased to below 140/90 mmHg to the same extent in both groups. Carotid IMT decreased significantly in the ARB group, but not in the non-ARB group, at 12 and 24 months after treatment. The urine levels of 8-OHdG decreased significantly at 6 and 12 months after treatment in the ARB group but did not decrease in the non-ARB group. The serum levels of NOx increased significantly at 6 and 12 months after treatment in the ARB group but not in the non-ARB group. In conclusion, candesartan decreases carotid IMT by enhancing NO production and decreasing oxidative stress in patients with hypertension.
Similar content being viewed by others
Article PDF
References
Kannel WB : Hypertension as a risk factor for cardiac events. Epidemiologic results of long-term studies. J Cardiovasc Pharmacol 1993; 21 ( Suppl 2): 27–37.
Furumoto T, Saito N, Dong J, Mikami T, Fujii S, Kitabatake A : Association of cardiovascular risk factors and endothelial dysfunction in Japanese hypertensive patients: implications for early atherosclerosis. Hypertens Res 2002; 25: 475–483.
Jacoby DS, Rader DJ : Renin-angiotensin system and atherosclerotic disease: from genes to treatment. Arch Intern Med 2003; 163: 1155–1164.
Unger T : The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89 ( Suppl): 3A–10A.
Petrovic I, Petrovic D, Vukovic N, et al: Ventricular and vascular remodeling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 2005; 33 ( Suppl 1): 39A–49A.
Olsen MH, Wachtell K, Neland K, et al: Losartan but not atenolol reduce carotid artery hypertrophy in essential hypertension. A LIFE substudy. Blood Press 2005; 14: 177–183.
Keaney JF Jr : Oxidative stress and the vascular wall NADPH oxidases take center stage. Circulation 2005; 112: 2585–2588.
Escobales N, Crespo MJ : Angiotensin II–dependent vascular alterations in young cardiomyopathic hamsters: role for oxidative stress. Vascul Pharmacol 2006; 44: 22–28.
Ignarro LJ, Napoli C : Novel features of nitric oxide, endothelial nitric oxide synthase, and atherosclerosis. Curr Diab Rep 2005; 5: 17–23.
Cosentino F, Savoia C, De Paolis P, et al: Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Am J Hypertens 2005; 18: 493–499.
Yagi S, Morita T, Katayama S : Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2004; 27: 129–135.
Chambless LE, Heiss G, Folsom AR, et al: Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the atherosclerosis risk in communities (ARIC) study, 1987–1993. Am J Epidemiol 1997; 146: 483–494.
Handa N, Matsumoto M, Maeda H, et al: Ultrasonic evaluation of early carotid atherosclerosis. Stroke 1990; 21: 1567–1572.
Kannel WB, D'Agostino RB, Sullivan L, Wilson PW : Concept and usefulness of cardiovascular risk profiles. Am Heart J 2004; 148: 16–26.
Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reduction in blood pressure overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827–839.
Wang JG, Staessen JA, Van Bortel LM, et al: Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006; 37: 1933–1940.
Simon A, Gariepy J, Moyse D, Levenson J : Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. Circulation 2001; 103: 2949–2954.
Borhani NO, Mercuri M, Borhani PA, et al: Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA 1996; 276: 785–791.
Hannan RE, Davis EA, Widdop RE : Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor–mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol 2003; 140: 987–995.
Hiyoshi H, Yayama K, Takano M, Okamoto H : Stimulation of cyclic GMP production via AT2 and B2 receptors in the pressure-overloaded aorta after banding. Hypertension 2004; 43: 1258–1263.
Muller S, Konig I, Meyer W, Kojda G : Inhibition of vascular oxidative stress in hypercholesterolemia by eccentric isosorbide mononitrate. J Am Coll Cardiol 2004; 44: 624–631.
Zeballos GA, Bernstein RD, Thompson CI, et al: Pharmacodynamics of plasma nitrate/nitrite as an indication of nitric oxide formation in conscious dogs. Circulation 1995; 91: 2982–2988.
Wang J, Brown MA, Tam SH, et al: Effects of diet on measurement of nitric oxide metabolites. Clin Exp Pharmacol Physiol 1997; 24: 418–420.
Mizushima Y, Kan S, Yoshida S, Sasaki S, Aoyama S, Nishida T : Changes in urinary levels of 8-hydroxy-2′-deoxyguanosine due to aging and smoking. Geratr Gerontol Int 2001; 1: 52–55.
Laursen JB, Rajagopalan S, Galis Z, et al: Role of superoxide in angiotensin II–induced but not catecholamine-induced hypertension. Circulation 1997; 95: 588–593.
Harrison DG : Endothelial function and oxidant stress. Clin Cardiol 1997; 20 ( Suppl II): 11–17.
Mancini JGB, Henry GC, Macaya C, et al: Angiotensin converting enzyme inhibition with quinapril improves endothelial dysfunction in patients with coronary artery disease. Circulation 1996; 94: 258–265.
Prasad A, Tupas-Habib T, Schenke WH, et al: Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349–2354.
Yagi S, Morita T, Katayama S : Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress. Hypertens Res 2006; 27: 129–136.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ono, H., Minatoguchi, S., Watanabe, K. et al. Candesartan Decreases Carotid Intima-Media Thickness by Enhancing Nitric Oxide and Decreasing Oxidative Stress in Patients with Hypertension. Hypertens Res 31, 271–279 (2008). https://doi.org/10.1291/hypres.31.271
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.271